These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 6701474)

  • 1. Binding and activation of the first complement component by soluble immune complexes: effect of complex size and composition.
    Doekes G; van Es LA; Daha MR
    Scand J Immunol; 1984 Feb; 19(2):99-110. PubMed ID: 6701474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the first component of complement, C1, by a monoclonal antibody recognizing the C chain of C1q.
    Heinz HP; Burger R; Golan MD; Loos M
    J Immunol; 1984 Feb; 132(2):804-8. PubMed ID: 6606678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.
    Doekes G; van Es LA; Daha MR
    Immunology; 1983 Jun; 49(2):215-22. PubMed ID: 6852866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of aggregate size on the binding and activation of the first component of human complement by soluble IgG aggregates.
    Doekes G; Vanes LA; Daha MR
    Immunology; 1982 Apr; 45(4):705-13. PubMed ID: 7068172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of reduction and alkylation on structure and function of rabbit IgG antibody--II. Effects on classical pathway C3 convertase formation.
    Johnson BA; Hoffmann LG
    Mol Immunol; 1984 Jan; 21(1):77-87. PubMed ID: 6561390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune complex mediated activation of the classical complement pathway.
    Borsos T
    Behring Inst Mitt; 1989 Jul; (84):93-101. PubMed ID: 2478118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of C1, C1-inactivator and C4 in modulating immune precipitation.
    Schifferli JA; Steiger G; Schapira M
    Clin Exp Immunol; 1985 Jun; 60(3):605-12. PubMed ID: 4017288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of the complement activation capacity of soluble IgG aggregates and immune complexes by IgM-rheumatoid factor.
    Doekes G; Schouten J; Cats A; Daha MR
    Immunology; 1985 Jul; 55(3):555-64. PubMed ID: 4018839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible mechanisms of the first step of the classical complement activation pathway: binding and activation of C1.
    Füst G; Medgyesi GA; Rajnavölgyi E; Csécsi-Nagy M; Czikora K; Gergely J
    Immunology; 1978 Dec; 35(6):873-84. PubMed ID: 104923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody density on rat red cells determines the rate of activation of the complement component C1.
    Hughes-Jones NC; Gorick BD; Howard JC; Feinstein A
    Eur J Immunol; 1985 Oct; 15(10):976-80. PubMed ID: 2996908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ
    J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of specific antibody on antibody-independent interactions between E. coli J5 and human complement.
    Betz SJ; Page N; Estrade C; Isliker H
    J Immunol; 1982 Feb; 128(2):707-11. PubMed ID: 7033382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of immune precipitation by purified classical pathway complement components.
    Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
    Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The distortive mechanism for the activation of complement component C1 supported by studies with a monoclonal antibody against the "arms" of C1q.
    Hoekzema R; Martens M; Brouwer MC; Hack CE
    Mol Immunol; 1988 May; 25(5):485-94. PubMed ID: 3261834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The modulation of immune complex aggregation by classical pathway-mediated reactions.
    Gronski P; Bodenbender L; Kanzy EJ; Loos M; Seiler FR
    Immunobiology; 1985 May; 169(4):346-61. PubMed ID: 3874147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-complexes solubilization: effect of antigen-antibody ratio and relative role of alternative and classical complement pathways.
    Genin C; Lesavre P
    Mol Immunol; 1983 Oct; 20(10):1069-72. PubMed ID: 6674809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetanus toxoid-anti-tetanus toxoid complexes: a potential model to study the complement transport system for immune complex in humans.
    Paccaud JP; Steiger G; Sjöholm AG; Spaeth PJ; Schifferli JA
    Clin Exp Immunol; 1987 Aug; 69(2):468-76. PubMed ID: 2958199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding and activation of human precursor C1 by soluble aggregates of human and rabbit IgG.
    Doekes G; van Seggelen-van Zijp AC; van Es LA; Cats A; Daha MR
    Int Arch Allergy Appl Immunol; 1985; 78(3):256-9. PubMed ID: 4055078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of the immune complex-complement interaction by protein H of the alternative complement pathway and the natural inhibitor heparin.
    Spycher MO; Nydegger UE
    Eur J Immunol; 1984 Mar; 14(3):276-9. PubMed ID: 6231187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The complement subcomponent C1q mediates binding of immune complexes and aggregates to endothelial cells in vitro.
    Daha MR; Miltenburg AM; Hiemstra PS; Klar-Mohamad N; Van Es LA; Van Hinsbergh VW
    Eur J Immunol; 1988 May; 18(5):783-7. PubMed ID: 3259929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.